NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pieris Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.28 -0.17 (-4.93 %) (As of 01/24/2020 11:21 AM ET) Add Compare Today's Range$3.28Now: $3.28▼$3.4550-Day Range$3.14MA: $3.38▼$3.6252-Week Range$2.44Now: $3.28▼$6.04Volume6,501 shsAverage Volume386,361 shsMarket Capitalization$180.33 millionP/E RatioN/ADividend YieldN/ABeta1.28 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PIRS Previous Symbol CUSIPN/A CIK1583648 Webhttp://www.pieris.com/ Phone857-246-8998Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio2.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$29.10 million Price / Sales6.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book4.43Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-26,750,000.00 Net Margins-107.24% Return on Equity-132.02% Return on Assets-27.99%Miscellaneous Employees107 Outstanding Shares54,980,000Market Cap$180.33 million Next Earnings Date3/16/2020 (Estimated) OptionableOptionable Receive PIRS News and Ratings via Email Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PIRS Rates by TradingView Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions What is Pieris Pharmaceuticals' stock symbol? Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS." How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.18. The biotechnology company earned $15.13 million during the quarter, compared to analysts' expectations of $6.28 million. Pieris Pharmaceuticals had a negative net margin of 107.24% and a negative return on equity of 132.02%. View Pieris Pharmaceuticals' Earnings History. When is Pieris Pharmaceuticals' next earnings date? Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Pieris Pharmaceuticals. What price target have analysts set for PIRS? 4 brokers have issued 1 year target prices for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $7.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals. What is the consensus analysts' recommendation for Pieris Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals. What are Wall Street analysts saying about Pieris Pharmaceuticals stock? Here are some recent quotes from research analysts about Pieris Pharmaceuticals stock: 1. According to Zacks Investment Research, "Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. " (1/23/2020) 2. William Blair analysts commented, "Wenzel is considered a global expert in the treatment of asthma and has extensive experience in conducting clinical trials in asthma patients, having been a lead author on the Phase II trials of Dupixent (Wenzel et al., 2016) and a co-author in the Phase III pivotal trial. The call reaffirmed that FeNO is a well-validated clinical marker of biological activity in patients with asthma, and our belief that there is a significant market opportunity for PRS-060, an inhaled Anticalin targeting IL-4Rα." (8/16/2019) 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and price target of $7. Currently our valuation is based on the three lead assets at the company: (1) PRS-060 for asthma, which is partnered with AstraZeneca contributing 33% of our valuation; (2) PRS-343 for oncology, which currently contributes 39% of our valuation; and (3) PRS-080 for functional iron deficiency anemia contributing 28% of our valuation. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (8/1/2019) Has Pieris Pharmaceuticals been receiving favorable news coverage? Media coverage about PIRS stock has trended negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pieris Pharmaceuticals earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Pieris Pharmaceuticals. Are investors shorting Pieris Pharmaceuticals? Pieris Pharmaceuticals saw a drop in short interest in December. As of December 31st, there was short interest totalling 1,750,000 shares, a drop of 6.9% from the December 15th total of 1,880,000 shares. Based on an average trading volume of 546,900 shares, the days-to-cover ratio is currently 3.2 days. Currently, 3.6% of the shares of the company are short sold. View Pieris Pharmaceuticals' Current Options Chain. Who are some of Pieris Pharmaceuticals' key competitors? Some companies that are related to Pieris Pharmaceuticals include Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), Anavex Life Sciences (AVXL), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), Vitality Biopharma (VBIO), US Stem Cell (USRM), Geovax Labs (GOVX) and Protalex (PRTX). What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), TG Therapeutics (TGTX), Nektar Therapeutics (NKTR), Omeros (OMER), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Iovance Biotherapeutics (IOVA) and Progenics Pharmaceuticals (PGNX). Who are Pieris Pharmaceuticals' key executives? Pieris Pharmaceuticals' management team includes the folowing people: Mr. Stephen S. Yoder, CEO, Pres & Director (Age 43)Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 44)Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 68)Mr. Claus Schalper MBA, Co-Founder & Sr. AdvisorMaria Kelman, Director of Investor Relations Who are Pieris Pharmaceuticals' major shareholders? Pieris Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Strs Ohio (0.25%) and Alpine Global Management LLC (0.04%). Company insiders that own Pieris Pharmaceuticals stock include Bvf Partners L P/Il, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals. Which major investors are selling Pieris Pharmaceuticals stock? PIRS stock was sold by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. View Insider Buying and Selling for Pieris Pharmaceuticals. Which major investors are buying Pieris Pharmaceuticals stock? PIRS stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Pieris Pharmaceuticals' stock price today? One share of PIRS stock can currently be purchased for approximately $3.28. How big of a company is Pieris Pharmaceuticals? Pieris Pharmaceuticals has a market capitalization of $180.33 million and generates $29.10 million in revenue each year. The biotechnology company earns $-26,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.View Additional Information About Pieris Pharmaceuticals. What is Pieris Pharmaceuticals' official website? The official website for Pieris Pharmaceuticals is http://www.pieris.com/. How can I contact Pieris Pharmaceuticals? Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected] MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 255 (Vote Outperform)Underperform Votes: 231 (Vote Underperform)Total Votes: 486MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: Pattern Day Trader
